MD Quote, Financials, Valuation and Earnings

Encompass Health Corp. has a net margin of 14.55% compared to Pediatrix Medical Group, Inc.'s net margin of 11.82%. Pediatrix Medical Group, Inc.'s return on equity of 20.22% beat Encompass Health Corp.'s return on equity of 24.34%.

Pediatrix Medical Group, Inc. has a consensus price target of $22.67, signalling upside risk potential of 2.06%. On the other hand Encompass Health Corp. has an analysts' consensus of $140.33 which suggests that it could grow by 41.22%. Given that Encompass Health Corp. has higher upside potential than Pediatrix Medical Group, Inc., analysts believe Encompass Health Corp. is more attractive than Pediatrix Medical Group, Inc..

Pediatrix Medical Group, Inc. has a beta of 0.735, which suggesting that the stock is 26.542% less volatile than S&P 500. In comparison Encompass Health Corp. has a beta of 0.756, suggesting its less volatile than the S&P 500 by 24.396%.

Pediatrix Medical Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Encompass Health Corp. offers a yield of 0.73% to investors and pays a quarterly dividend of $0.19 per share. Pediatrix Medical Group, Inc. pays -- of its earnings as a dividend. Encompass Health Corp. pays out 14.35% of its earnings as a dividend. Encompass Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Pediatrix Medical Group, Inc. quarterly revenues are $492.9M, which are smaller than Encompass Health Corp. quarterly revenues of $1.5B. Pediatrix Medical Group, Inc.'s net income of $71.7M is lower than Encompass Health Corp.'s net income of $174.7M. Notably, Pediatrix Medical Group, Inc.'s price-to-earnings ratio is 11.72x while Encompass Health Corp.'s PE ratio is 18.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pediatrix Medical Group, Inc. is 0.99x versus 1.75x for Encompass Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Kindly MD, Inc. has a net margin of 14.55% compared to Pediatrix Medical Group, Inc.'s net margin of -22162.75%. Pediatrix Medical Group, Inc.'s return on equity of 20.22% beat Kindly MD, Inc.'s return on equity of -91.57%.

Pediatrix Medical Group, Inc. has a consensus price target of $22.67, signalling upside risk potential of 2.06%. On the other hand Kindly MD, Inc. has an analysts' consensus of $1.25 which suggests that it could grow by 211.41%. Given that Kindly MD, Inc. has higher upside potential than Pediatrix Medical Group, Inc., analysts believe Kindly MD, Inc. is more attractive than Pediatrix Medical Group, Inc..

Pediatrix Medical Group, Inc. has a beta of 0.735, which suggesting that the stock is 26.542% less volatile than S&P 500. In comparison Kindly MD, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pediatrix Medical Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kindly MD, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pediatrix Medical Group, Inc. pays -- of its earnings as a dividend. Kindly MD, Inc. pays out -- of its earnings as a dividend.

Pediatrix Medical Group, Inc. quarterly revenues are $492.9M, which are larger than Kindly MD, Inc. quarterly revenues of $388.2K. Pediatrix Medical Group, Inc.'s net income of $71.7M is higher than Kindly MD, Inc.'s net income of -$86M. Notably, Pediatrix Medical Group, Inc.'s price-to-earnings ratio is 11.72x while Kindly MD, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pediatrix Medical Group, Inc. is 0.99x versus 11.25x for Kindly MD, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

The Oncology Institute, Inc. has a net margin of 14.55% compared to Pediatrix Medical Group, Inc.'s net margin of -10.08%. Pediatrix Medical Group, Inc.'s return on equity of 20.22% beat The Oncology Institute, Inc.'s return on equity of -9486.64%.

Pediatrix Medical Group, Inc. has a consensus price target of $22.67, signalling upside risk potential of 2.06%. On the other hand The Oncology Institute, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 81.06%. Given that The Oncology Institute, Inc. has higher upside potential than Pediatrix Medical Group, Inc., analysts believe The Oncology Institute, Inc. is more attractive than Pediatrix Medical Group, Inc..

Pediatrix Medical Group, Inc. has a beta of 0.735, which suggesting that the stock is 26.542% less volatile than S&P 500. In comparison The Oncology Institute, Inc. has a beta of 0.151, suggesting its less volatile than the S&P 500 by 84.902%.

Pediatrix Medical Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Oncology Institute, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pediatrix Medical Group, Inc. pays -- of its earnings as a dividend. The Oncology Institute, Inc. pays out -- of its earnings as a dividend.

Pediatrix Medical Group, Inc. quarterly revenues are $492.9M, which are larger than The Oncology Institute, Inc. quarterly revenues of $136.6M. Pediatrix Medical Group, Inc.'s net income of $71.7M is higher than The Oncology Institute, Inc.'s net income of -$13.8M. Notably, Pediatrix Medical Group, Inc.'s price-to-earnings ratio is 11.72x while The Oncology Institute, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pediatrix Medical Group, Inc. is 0.99x versus 0.67x for The Oncology Institute, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

U.S. Physical Therapy, Inc. has a net margin of 14.55% compared to Pediatrix Medical Group, Inc.'s net margin of 9.98%. Pediatrix Medical Group, Inc.'s return on equity of 20.22% beat U.S. Physical Therapy, Inc.'s return on equity of 8.6%.

Pediatrix Medical Group, Inc. has a consensus price target of $22.67, signalling upside risk potential of 2.06%. On the other hand U.S. Physical Therapy, Inc. has an analysts' consensus of $105.33 which suggests that it could grow by 20.42%. Given that U.S. Physical Therapy, Inc. has higher upside potential than Pediatrix Medical Group, Inc., analysts believe U.S. Physical Therapy, Inc. is more attractive than Pediatrix Medical Group, Inc..

Pediatrix Medical Group, Inc. has a beta of 0.735, which suggesting that the stock is 26.542% less volatile than S&P 500. In comparison U.S. Physical Therapy, Inc. has a beta of 1.290, suggesting its more volatile than the S&P 500 by 28.981%.

Pediatrix Medical Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. U.S. Physical Therapy, Inc. offers a yield of 2.06% to investors and pays a quarterly dividend of $0.45 per share. Pediatrix Medical Group, Inc. pays -- of its earnings as a dividend. U.S. Physical Therapy, Inc. pays out 95.62% of its earnings as a dividend. U.S. Physical Therapy, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Pediatrix Medical Group, Inc. quarterly revenues are $492.9M, which are larger than U.S. Physical Therapy, Inc. quarterly revenues of $197.1M. Pediatrix Medical Group, Inc.'s net income of $71.7M is higher than U.S. Physical Therapy, Inc.'s net income of $19.7M. Notably, Pediatrix Medical Group, Inc.'s price-to-earnings ratio is 11.72x while U.S. Physical Therapy, Inc.'s PE ratio is 36.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pediatrix Medical Group, Inc. is 0.99x versus 1.75x for U.S. Physical Therapy, Inc.. Usually stocks with elevated PS ratios are considered overvalued.